WARNER-LAMBERT REZULIN sNDA FOR BROAD TYPE II DIABETES INDICATION WILL BE FILED SHORTLY; PHASE IV STUDY WILL LOOK AT VOLUME EXPANSION IN SEVERE CHF PATIENTS
Executive Summary
Warner-Lambert plans to file an NDA supplement "shortly" to expand the indication of its oral antidiabetic Rezulin (troglitazone) to treatment of type II diabetes patients as monotherapy or in combination with sulfonylureas, Warner-Lambert Senior Director-Clinical Research, Diabetes & Metabolic Diseases Randall Whitcomb, MD, said during a Jan. 30 teleconference announcing the drug's approval.